{"id":538028,"date":"2021-09-14T09:28:23","date_gmt":"2021-09-14T13:28:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/"},"modified":"2021-09-14T09:28:23","modified_gmt":"2021-09-14T13:28:23","slug":"cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/","title":{"rendered":"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">MONMOUTH JUNCTION, N.J.<\/span>, <span class=\"xn-chron\">Sept. 14, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=2749257710&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" rel=\"nofollow noopener\">CytoSorbents Corporation<\/a><\/u>\u00a0(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=920976045&amp;u=https%3A%2F%2Fcyto.news%2FIEM-210916&amp;a=live+webinar\" rel=\"nofollow noopener\">live webinar<\/a>\u00a0to provide a global perspective on CytoSorb<sup>\u00ae<\/sup> blood purification therapy in COVID-19 patients on <span class=\"xn-chron\">Thursday September 16, 2021<\/span>, at <span class=\"xn-chron\">11 a.m. EDT<\/span> \/ <span class=\"xn-chron\">5:00 p.m. CET<\/span>.\u00a0 The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COVID-19 patients worldwide, including the recently announced topline results from the <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=482034076&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Ftopline-results-from-cytosorbents-us-ctc-multicenter-registry-demonstrate-high-survival-using-cytosorb-in-critically-ill-covid-19-patients-on-extracorporeal-membrane-oxygenation-ecmo-301367025.html&amp;a=U.S.+multicenter+CTC+Registry+using+CytoSorb+with+ECMO+under+U.S.+FDA+Emergency+Use+Authorization\" rel=\"nofollow noopener\">U.S. multicenter CTC Registry using CytoSorb with ECMO under U.S. FDA Emergency Use Authorization<\/a>.\u00a0\u00a0<\/p>\n<div id=\"prni_dvprnejpgeb6cleft\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpgeb6cleft\" title=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses and during cardiac surgery with its flagship product, CytoSorb.  CytoSorb is approved in the European Union and distributed in 67 countries worldwide.\" border=\"0\" alt=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses and during cardiac surgery with its flagship product, CytoSorb.  CytoSorb is approved in the European Union and distributed in 67 countries worldwide.\" align=\"middle\" src=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n      <\/div>\n<p>\n        <b><br \/>\n          <u>Live Webinar details:<\/u><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <u><br \/>\n            <br \/>\n          <\/u><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3589653990&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents%2Fvideos%2F555553852423407%2F&amp;a=Update+on+CytoSorb+Therapy+in+COVID-19+Patients\" rel=\"nofollow noopener\">Update on CytoSorb Therapy in COVID-19 Patients<\/a><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <br \/>\n          <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=471032397&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents%2Fvideos%2F555553852423407%2F&amp;a=CytoSorbents%27+International+Experts+Meeting+in+Intensive+Care+Series\" rel=\"nofollow noopener\">CytoSorbents&#8217; International Experts Meeting in Intensive Care Series<\/a><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Date:<\/b>\u00a0Thursday, September 16, 2021<br \/><b>Time:<\/b>\u00a011:00 a.m. Eastern \/ <span class=\"xn-chron\">5:00 p.m. CET<\/span><br \/><b>Registration Link:<\/b>\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=534189115&amp;u=https%3A%2F%2Fcyto.news%2FIEM-210916&amp;a=https%3A%2F%2Fcyto.news%2FIEM-210916\" rel=\"nofollow noopener\">https:\/\/cyto.news\/IEM-210916<\/a><\/p>\n<p>\n        <b><br \/>\n          <u>Chairperson:<\/u><br \/>\n        <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Dr. <span class=\"xn-person\">Manu Shakar-Hari<\/span>, <span class=\"xn-location\">London\/UK<\/span><\/b>\n        <\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <u>Speakers:<\/u><br \/>\n        <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Dr. <span class=\"xn-person\">Tae Song<\/span>, <span class=\"xn-location\">Chicago<\/span>\/<span class=\"xn-location\">USA<\/span><br \/><\/b><br \/>\n          <i>Topline results from the U.S. CTC multicenter registry<\/i>\n        <\/li>\n<li>\n          <b>Dr. <span class=\"xn-person\">Zsolt Moln<\/span><\/b><br \/>\n          <b>\u00e1<\/b><br \/>\n          <b>r, <span class=\"xn-location\">Budapest\/Hungary<\/span><br \/><\/b><br \/>\n          <i>Overview about current studies and experiences<\/i>\n        <\/li>\n<li>\n          <b>Dr. Manu Shankar-Hari, <span class=\"xn-location\">London\/UK<\/span><br \/><\/b><br \/>\n          <i>Multisystem inflammatory syndrome<\/i>\n        <\/li>\n<\/ul>\n<p>The session will conclude with a live, moderated Question and Answer session.<\/p>\n<p>\n        <b>Highlighted data to be presented are expected to include:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1560968688&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Ftopline-results-from-cytosorbents-us-ctc-multicenter-registry-demonstrate-high-survival-using-cytosorb-in-critically-ill-covid-19-patients-on-extracorporeal-membrane-oxygenation-ecmo-301367025.html&amp;a=Topline+results\" rel=\"nofollow noopener\">Topline results<\/a>\u00a0from the U.S. CytoSorb Therapy in COVID-19 (CTC) Registry, reporting 73% 90-day survival in 52 critically-ill COVID-19 patients in refractory respiratory failure on ECMO and CytoSorb under <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=2514319263&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fus-fda-grants-cytosorb-emergency-use-authorization-for-use-in-patients-with-covid-19-infection-301039293.html&amp;a=FDA+Emergency+Use+Authorization\" rel=\"nofollow noopener\">FDA Emergency Use Authorization<\/a> at 5 U.S. ECMO centers.<sup>1<\/sup><\/li>\n<li>Consistently reported key clinical parameters including: <\/li>\n<ul type=\"circle\">\n<li>Reductions of inflammatory marker levels, including IL-6, CRP and ferritin (<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1678054527&amp;u=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34336280%2F&amp;a=Ruiz-Rodriguez\" rel=\"nofollow noopener\">Ruiz-Rodriguez<\/a><sup>2<\/sup>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=580951305&amp;u=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Faor.13864&amp;a=Alharthy\" rel=\"nofollow noopener\">Alharthy<\/a><u><sup>3<\/sup><\/u>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1546573934&amp;u=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34152629%2F&amp;a=Nassiri\" rel=\"nofollow noopener\">Nassiri<\/a><u><sup>4<\/sup><\/u>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3917617430&amp;u=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34219277%2F&amp;a=Geraci\" rel=\"nofollow noopener\">Geraci<\/a><u><sup>5<\/sup><\/u>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=2250414140&amp;u=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34407530%2F&amp;a=Peng\" rel=\"nofollow noopener\">Peng<\/a><u><sup>6<\/sup><\/u>, and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1219313291&amp;u=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2F10.1177%2F03913988211030517&amp;a=Wunderlich-Sperl\" rel=\"nofollow noopener\">Wunderlich-Sperl<\/a><u><sup>7<\/sup><\/u><\/li>\n<li>Improvements in hemodynamic stabilization and weaning of vasopressors (Ruiz-Rodriguez, Nassiri, Peng, Wunderlich-Sperl) <\/li>\n<li>Improvements in the P\/F ratio, considered to be one of the most clinically relevant measures of lung function in ventilated patients (Ruiz-Rodriguez, Alharthy, Peng, Wunderlich-Sperl)<\/li>\n<\/ul>\n<li>The importance of starting CytoSorb therapy in COVID-19 patients with confirmed respiratory failure, before they develop irreversible organ injury.\u00a0 Intervening before fulminant thrombotic ischemic injury has occurred, as evidenced by very high baseline D-dimer levels appears to be particularly important. \u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3523647222&amp;u=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F%3Fterm%3Dd-dimer%2Bcovid-19&amp;a=Multiple+studies\" rel=\"nofollow noopener\">Multiple studies<\/a> have identified high D-dimers as a significant risk factor for poor outcome and mortality in critically ill COVID-19 patients, regardless of whether cytokine adsorption is used or not.<\/li>\n<\/ul>\n<p>Dr. <span class=\"xn-person\">Joerg Scheier<\/span>, Vice President of Medical and Clinical Affairs of CytoSorbents, stated, &#8220;We are excited to see that the expanding numbers of positive clinical experiences with CytoSorb in COVID-19 patients are now being reflected by an increasing number of scientific peer review publications from many different geographies.\u00a0 We believe the ability to reduce inflammatory mediators in these patients is a key reason that common clinical benefits are being reported in COVID-19 patients treated with CytoSorb.\u00a0 Finally, clinicians routinely comment that CytoSorb is easy to use, irrespective of whether the device is set up within a renal replacement, an extracorporeal membrane oxygenation (ECMO), or a standalone circuit in hemoperfusion mode. This has given physicians greater flexibility in how and when they treat patients with CytoSorb.&#8221;<\/p>\n<p>Overall, CytoSorb has been used in more than 6,500 critically ill COVID-19 patients in more than 30 countries worldwide to reduce cytokine storm and other circulating inflammatory mediators with the goals of reducing severe systemic hyper-inflammation and damage to vital organs like the lungs, heart, and kidneys, while improving the chances of survival.<\/p>\n<p>References:<\/p>\n<ol type=\"1\">\n<li>Song, T et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=4195145621&amp;u=https%3A%2F%2Fwww.isicem.org%2Fadmin%2Fupload%2Fabstract%2F1079190621%2FP%2FP139.pdf&amp;a=CytoSorb+Therapy+in+COVID-19+(CTC)+Patients+Requiring+Extracorporeal+Membrane+Oxygenation%3A%C2%A0+A+Multicenter%2C+Retrospective+Registry\" rel=\"nofollow noopener\">CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation:\u00a0 A Multicenter, Retrospective Registry<\/a>.&#8221; <i>Intl Symposium on Intensive Care and Emergency Medicine Presentation &#8211;<\/i><span class=\"xn-chron\">August 2021<\/span><\/li>\n<li>Ruiz-Rodriguez JC, et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1537628469&amp;u=https%3A%2F%2Fdownloads.hindawi.com%2Fjournals%2Fccrp%2F2021%2F7769516.pdf&amp;a=The+Use+of+CytoSorb+Therapy+in+Critically+Ill+COVID-19+Patients%3A+Review+of+the+Rationale+and+Current+Clinical+Experiences\" rel=\"nofollow noopener\">The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences<\/a>.&#8221; <i>Crit Care Res Pract.<\/i> 2021 <\/li>\n<li>Alharthy A, et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=2995734334&amp;u=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Fepdf%2F10.1111%2Faor.13864&amp;a=Continuous+Renal+Replacement+Therapy+with+the+Addition+of+CytoSorb+Cartridge+in+Critically+Ill+Patients+with+COVID-19+Plus+Acute+Kidney+Injury%3A+A+Case+Series\" rel=\"nofollow noopener\">Continuous Renal Replacement Therapy with the Addition of CytoSorb Cartridge in Critically Ill Patients with COVID-19 Plus Acute Kidney Injury: A Case Series<\/a>.&#8221; <i>Artificial Organs.<\/i> 2020 <\/li>\n<li>Nassiri AA, et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=2268864352&amp;u=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Fepdf%2F10.1111%2Faor.14024&amp;a=Blood+Purification+with+CytoSorb+in+Critically+Ill+COVID-19+Patients%3A+A+Case+Series+of+26+Patients\" rel=\"nofollow noopener\">Blood Purification with CytoSorb in Critically Ill COVID-19 Patients: A Case Series of 26 Patients<\/a>.&#8221; <i>Artif Organs<\/i>. 2021 <\/li>\n<li>Geraci T, et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=472294709&amp;u=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Fepdf%2F10.1111%2Fjocs.15785&amp;a=Hemoadsorption+for+Management+of+Patients+on+Veno-Venous+ECMO+Support+for+Severe+COVID-19+Acute+Respiratory+Distress+Syndrome\" rel=\"nofollow noopener\">Hemoadsorption for Management of Patients on Veno-Venous ECMO Support for Severe COVID-19 Acute Respiratory Distress Syndrome<\/a>.&#8221;\u00a0 <i>J. Cardiac Surg<\/i>. 2021 <\/li>\n<li>Peng JY, et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3740655434&amp;u=https%3A%2F%2Fwww.karger.com%2FArticle%2FPdf%2F517721&amp;a=Hemoperfusion+with+CytoSorb+in+Critically+Ill+COVID-19+Patients\" rel=\"nofollow noopener\">Hemoperfusion with CytoSorb in Critically Ill COVID-19 Patients<\/a>.&#8221; <i>Blood Purif<\/i>. 2021 <\/li>\n<li>Wunderlich-Sperl F, et al., &#8220;<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=4111873563&amp;u=https%3A%2F%2Fjournals.sagepub.com%2Fdoi%2Fabs%2F10.1177%2F03913988211030517&amp;a=Adjuvant+Hemoadsorption+Therapy+in+Patients+with+Severe+COVID-19+and+Related+Organ+Failure+Requiring+CRRT+or+ECMO+Therapy%3A+A+Case+Series\" rel=\"nofollow noopener\">Adjuvant Hemoadsorption Therapy in Patients with Severe COVID-19 and Related Organ Failure Requiring CRRT or ECMO Therapy: A Case Series<\/a>. <i>Int J Artif Organs<\/i>. 2021 <\/li>\n<\/ol>\n<p>\n        <b>About CytoSorbents Corporation (NASDAQ: <\/b><br \/>\n        <b>CTSO<\/b><br \/>\n        <b>) <\/b>\n      <\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1872839544&amp;u=https%3A%2F%2Fcytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" rel=\"nofollow noopener\">CytoSorbents Corporation<\/a>\u00a0is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.\u00a0 Its flagship product, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=959952770&amp;u=https%3A%2F%2Fcytosorb-therapy.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener\">CytoSorb<sup>\u00ae<\/sup><\/a>, is approved in the European Union with distribution in 68 countries around the world as an extracorporeal cytokine adsorber designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. \u00a0These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist.\u00a0 CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure.\u00a0 More than 143,000 CytoSorb devices have been delivered to date.\u00a0 CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber.\u00a0 Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=4014171583&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fcytosorb-is-approved-and-available-for-the-removal-of-ticagrelor-a-leading-anti-platelet-drug-during-cardiopulmonary-bypass-in-the-eu-300995215.html&amp;a=ticagrelor\" rel=\"nofollow noopener\">ticagrelor<\/a> and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3720476260&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fcytosorb-is-eu-approved-to-remove-rivaroxaban-a-leading-factor-xa-inhibitor-and-novel-oral-anticoagulant-during-on-pump-cardiothoracic-surgery-301057276.html&amp;a=rivaroxaban\" rel=\"nofollow noopener\">rivaroxaban<\/a> during cardiothoracic surgery.\u00a0 CytoSorb has also received <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=2514319263&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fus-fda-grants-cytosorb-emergency-use-authorization-for-use-in-patients-with-covid-19-infection-301039293.html&amp;a=FDA+Emergency+Use+Authorization\" rel=\"nofollow noopener\">FDA Emergency Use Authorization<\/a> in <span class=\"xn-location\">the United States<\/span> for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure.\u00a0 The DrugSorb-ATR\u2122 Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1398942051&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fdevelopment-update-us-fda-grants-breakthrough-designation-to-cytosorb-for-removal-of-ticagrelor-during-cardiopulmonary-bypass-in-emergent-and-urgent-cardiothoracic-surgery-301043326.html&amp;a=FDA%C2%A0Breakthrough+Designation\" rel=\"nofollow noopener\">FDA\u00a0Breakthrough Designation<\/a> for the removal of ticagrelor, as well as <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=914753366&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fsecond-us-fda-breakthrough-device-designation-granted-to-cytosorbents-drugsorb-atr-antithrombotic-removal-system-adding-the-removal-of-market-leading-direct-oral-anticoagulants-during-urgent-cardiothoracic-surgery-301354007.html&amp;a=FDA+Breakthrough+Designation\" rel=\"nofollow noopener\">FDA Breakthrough Designation<\/a> for the removal of the direct oral anticoagulant (DOAC) drugs rivaroxaban and apixaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.\u00a0 <\/p>\n<p>CytoSorb has been granted U.S. FDA Emergency Use Authorization in the COVID-19 pandemic\u00a0as an extracorporeal cytokine adsorber for use in adult, critically ill COVID-19 patients with imminent or confirmed respiratory failure.\u00a0 The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The CytoSorb device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the CytoSorb device under Section 564(b)(l) of the Act, 21 U.S.C \u00a7 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.<\/p>\n<p>CytoSorbents&#8217; purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. \u00a0Its technologies have received non-dilutive grant, contract, and other funding of more than <span class=\"xn-money\">$39.5 million<\/span> from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF\/AFMC), and others. \u00a0The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY<sup>\u00ae<\/sup>, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ<sup>\u00ae<\/sup>, K<sup>+<\/sup>ontrol\u2122, DrugSorb\u2122, DrugSorb-ATR\u2122, ContrastSorb, and others.\u00a0\u00a0For more information, please visit the Company&#8217;s websites at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=730154712&amp;u=https%3A%2F%2Fcytosorbents.com%2F&amp;a=www.cytosorbents.com\" rel=\"nofollow noopener\">www.cytosorbents.com<\/a> and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3339694511&amp;u=https%3A%2F%2Fcytosorb-therapy.com%2F&amp;a=www.cytosorb.com\" rel=\"nofollow noopener\">www.cytosorb.com<\/a> or follow us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3038350999&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents&amp;a=Facebook\" rel=\"nofollow noopener\">Facebook<\/a> and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1357900826&amp;u=https%3A%2F%2Ftwitter.com%2FCytoSorbents&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a>.\u00a0<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. \u00a0These forward-looking statements include, but are not limited to, statements about our plans, objectives, anticipated future results and performance, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. \u00a0You should be aware that the forward-looking statements in this press release represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on <span class=\"xn-chron\">March 9, 2021<\/span>, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. \u00a0We caution you not to place undue reliance upon any such forward-looking statements. \u00a0We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n<p>\n        <b><br \/>\n          <u>Please Click to Follow Us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=3038350999&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents&amp;a=Facebook\" rel=\"nofollow noopener\">Facebook<\/a> and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3289721-1&amp;h=1357900826&amp;u=https%3A%2F%2Ftwitter.com%2FCytoSorbents&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a><\/u><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Investor Relations Contact:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Terri Anne Powers<\/span><br \/>\n        <br \/>Vice President, Investor Relations <br \/>and Corporate Communications<br \/>(732) 482-9984<br \/><a target=\"_blank\" href=\"mailto:tpowers@cytosorbents.com\" rel=\"nofollow noopener\">tpowers@cytosorbents.com<\/a><\/p>\n<p>\n        <b>U.S. Public Relations Contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Eric Kim<\/span><br \/>\n        <br \/>Rubenstein Public Relations <br \/>212-805-3052 <br \/><a target=\"_blank\" href=\"mailto:ekim@rubensteinpr.com\" rel=\"nofollow noopener\">ekim@rubensteinpr.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY05939&amp;sd=2021-09-14\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19-301376193.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19-301376193.html<\/a><\/p>\n<p>SOURCE  CytoSorbents Corporation<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY05939&amp;Transmission_Id=202109140925PR_NEWS_USPR_____NY05939&amp;DateId=20210914\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients PR Newswire MONMOUTH JUNCTION, N.J., Sept. 14, 2021 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming live webinar\u00a0to provide a global perspective on CytoSorb\u00ae blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT \/ 5:00 p.m. CET.\u00a0 The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COVID-19 patients worldwide, including the recently announced topline results from &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538028","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients PR Newswire MONMOUTH JUNCTION, N.J., Sept. 14, 2021 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming live webinar\u00a0to provide a global perspective on CytoSorb\u00ae blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT \/ 5:00 p.m. CET.\u00a0 The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COVID-19 patients worldwide, including the recently announced topline results from &hellip; Continue reading &quot;CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-14T13:28:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19\",\"datePublished\":\"2021-09-14T13:28:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/\"},\"wordCount\":1566,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/\",\"name\":\"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"datePublished\":\"2021-09-14T13:28:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19 - Market Newsdesk","og_description":"Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients PR Newswire MONMOUTH JUNCTION, N.J., Sept. 14, 2021 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming live webinar\u00a0to provide a global perspective on CytoSorb\u00ae blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT \/ 5:00 p.m. CET.\u00a0 The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COVID-19 patients worldwide, including the recently announced topline results from &hellip; Continue reading \"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-14T13:28:23+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19","datePublished":"2021-09-14T13:28:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/"},"wordCount":1566,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/","name":"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","datePublished":"2021-09-14T13:28:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-critically-ill-patients-with-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb\u00ae in Critically Ill Patients with COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538028"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538028\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}